ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Induction therapy"

  • 2016 American Transplant Congress

    Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.

    N. Jasiak,1 C. Stromayer,1 J. Thielke,1 J. Chen,2 J. Chen,1 B. Talon,1 R. Rubin-Tobar,1 E. Benedetti,2 P. West-Thielke.1,2

    1Pharmacy, University of Illinois, Chicago; 2Transplant Surgery, University of Illinois, Chicago, IL.

    Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…
  • 2016 American Transplant Congress

    Outcomes of Depleting Antibody Induction in Kidney Transplantation: A Paired Kidney Analysis.

    M. Sampaio, B. Chopra, K. Sureshkumar.

    Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.

    Induction therapy can improve graft survival following kidney transplantation. Organ quality, a major determinant of graft outcomes may act as a confounder in comparative studies…
  • 2015 American Transplant Congress

    Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era

    B. Tanriover,1 S. Zhang,2 M. MacConmara.3

    1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.

    Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…
  • 2015 American Transplant Congress

    A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients

    M. Janusek,1 S. Patel,2 K. Galen,1 P. West-Thilke,1 E. Benedetti,1 J. Thielke.1

    1University of Illinois Hospital and Health Sciences System, Chicago, IL; 2VA Great Lakes Health Care System, Westchester, IL.

    Background:Greater than 90% of all kidney transplants(KTx) today receive an induction agent. The choice of a depleting or non-depleting agent is center specific. Alemtuzumab (Alem),…
  • 2015 American Transplant Congress

    Inadequate Overall Immunosuppression Is a Risk for Late Acute Rejection Despite Alemtuzumab Induction in Simultaneous Pancreas Kidney Transplant Recipients

    J. Bank,1 M. Mallat,1 P. van der Boog,1 D. Braat,2 J. Ringers,2 M. Vergunst,3 S. Heidt,3 F. Claas,3 M. Reinders,1 J. de Fijter.1

    1Nephrology, LUMC, Leiden, Netherlands; 2Surgery, LUMC, Leiden, Netherlands; 3IHB, LUMC, Leiden, Netherlands.

    Introduction: Simultaneous pancreas-kidney transplantation (SPK) has become the treatment of choice for patients with end-stage renal disease due to Type 1 Diabetes Mellitus. SPK is…
  • 2015 American Transplant Congress

    Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients

    A. Seitz,1 M. Robb,3 S. Balasubramanian,1 A. McLean,2 D. Taube,2 R. Johnson,3 R. Baker.1

    1Renal Unit, St. James's Hospital, Leeds, United Kingdom; 2West London Renal and Transplant, Hammersmith Hospital, London, United Kingdom; 3Organ Donation and Transplantation Studies, NHS Blood and Transplant, Bristol, United Kingdom.

    Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…
  • 2015 American Transplant Congress

    Infections After Alemtuzumab Induction: A Non Issue?

    A. Smith, M. John, I. Dortonne, A. Paramesh, M. Killackey, R. Zhang, B. Lee, J. Buell.

    Transplant Institute, Tulane University, New Orleans, LA.

    Background: Alemtuzumab is a powerful induction agent that depletes multiple lymphocyte cell lines resulting in leukopenia and/or neutropenia with concerns over infectious complications. This study…
  • 2015 American Transplant Congress

    Reduced Intensity Immunosuppression Protocol Lowers Drug Costs and May Decrease Incidences of BK Viremia and Readmissions After Kidney and Kidney/Pancreas Transplant

    M. Mariski,1 A. DeGolovine,2 W. Dar,2 J. Bynon,2 H. Adrogué,2 M. Hobeika.2

    1Dept of Pharmacy, Memorial Hermann Texas Medical Center, Houston, TX; 2Division of Immunology and Organ Transplantation, University of Texas, Houston, TX.

    Purpose: To evaluate the effects of a reduced intensity immunosuppression protocol on drug costs and rates of BK viremia and readmissions.Methods: In response to high…
  • 2015 American Transplant Congress

    Effectiveness of Protocol-Driven Induction Therapy in Adult Kidney Transplant Recipients

    J. Casale, J. Fleming, D. Taber, C. Staino, K. Boyle, K. Covert, N. Pilch, H. Meadows, C. Mardis, K. Chavin, C. Bratton, J. McGillicuddy, T. Srinivas, P. Baliga.

    MUSC, Charleston, SC.

    Background: Induction therapy significantly improves graft outcomes in kidney transplantation, but the optimal agent based on patient characteristics and immunologic risk is unknown. While many…
  • 2015 American Transplant Congress

    Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results

    J. Lee, J. Lee, D. Joo, K. Huh, S. Kim, Y. Kim, M. Kim.

    Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea.

    Proper management of delayed graft function (DGF) is essential for successful post-transplant result in deceased donor kidney transplantation. We compared the effect of anti-lymphocyte antibody…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 31
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences